Company profile: Cynapsus Therapeutics
1.1 - Company Overview
Company description
- Provider of healthcare, biotechnology, and pharmaceutical therapeutics focused on Parkinson's disease, developing non-injectable treatments including APL-130277, a fast-acting, easy-to-use sublingual thin film for on-demand management of OFF episodes.
Products and services
- Non-Injectable Parkinson’s Drug Development: Architects a non-injectable therapy for Parkinson’s disease using sublingual thin-film administration to enable on-demand management of OFF episodes, emphasizing fast-acting, easy-to-use dosing
- APL-130277: A fast-acting, easy-to-use sublingual thin film engineered for on-demand management of OFF episodes in Parkinson’s disease, enabling non-injectable administration
- Therapeutics Specialization in Healthcare and Biotechnology: Engineers pharmaceutical therapeutics focused on developing a non-injectable Parkinson’s drug in sublingual thin-film format for on-demand management of OFF episodes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cynapsus Therapeutics
Coaxia
HQ: United States
Website
- Description: Provider of medical device research and development focused on therapy and treatment solutions for cerebral ischemia; based in Minneapolis, MN.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coaxia company profile →
NKGen Biotech
HQ: United States
Website
- Description: Provider of natural killer (NK) cell therapy candidates to restore immune function for cancer treatment, including SNK01, an autologous NK therapy in clinical trials for neurodegenerative diseases and various cancers, and SNK02, an allogeneic NK therapy being tested for solid tumors, plus an Expanded Access Program enabling access to investigational therapies under specific conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NKGen Biotech company profile →
Kineta
HQ: United States
Website
- Description: Provider of biotechnology drug discovery focused on diseases caused by protein misfolding, offering immunotherapies such as KVA12123, a VISTA-blocking agent in Phase 1/2 trials as monotherapy and with pembrolizumab, and an anti-CD27 agonist mAb to activate T and NK cells and address exhausted T cells in the tumor microenvironment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kineta company profile →
Catalyst Pharmaceuticals
HQ: United States
Website
- Description: Provider of prescription drug development and commercialization, offering FIRDAPSE (FDA-approved for adults with Lambert-Eaton myasthenic syndrome) and FYCOMPA (for partial-onset seizures in individuals 4+ and primary generalized tonic-clonic seizures in those 12+). Supports investigator-sponsored research in LEMS and hereditary neuropathy and provides a U.S. expanded access program offering its lead product at no charge prior to FDA approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Catalyst Pharmaceuticals company profile →
MyndTec
HQ: Canada
Website
- Description: Provider of medical devices focused on the treatment of stroke, spinal cord injury (SCI), and other brain-related disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MyndTec company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cynapsus Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cynapsus Therapeutics
2.2 - Growth funds investing in similar companies to Cynapsus Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cynapsus Therapeutics
4.2 - Public trading comparable groups for Cynapsus Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →